Advanced Cell Technology to Participate on Panels and Host Experts Luncheon at 2012 World Stem Cell Summit

  Advanced Cell Technology to Participate on Panels and Host Experts Luncheon
  at 2012 World Stem Cell Summit

 Company Executives to Discuss Three Ongoing Clinical Trials in the U.S. and
Europe as well as Legal and Policy Challenges to Regenerative Medicine Sector

World Stem Cell Summit 2012

Business Wire

MARLBOROUGH, Mass. -- December 03, 2012

Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC or the “Company”), a leader
in the field of regenerative medicine, announced today that the company is a
sponsor of the 2012 World Stem Cell Summit , Dec. 3-5 at the Palm Beach County
Convention \Center in West Palm Beach, Florida. The Company will host an
“Experts Luncheon” and chairman and CEO Gary Rabin and director of business
development Matthew Vincent, Ph.D., will also serve on panels at the event.

On Monday, Dec. 3, Dr. Vincent will host a “Conversation with Experts
Luncheon” at which he will meet with conference attendees to discuss the
Company’s programs and the future of regenerative medicine and stem cell
therapies.

Also on Monday, Dec. 3, at 4:00 p.m. EST Dr. Vincent will serve on a panel
titled  “Understanding the Legal and Policy Challenges to Stem Cell Research”
and on Tuesday, Dec. 4, at 10:30 a.m. EST Mr. Rabin will be part of a
“Clinical Trial Update” session, providing an update on the Company’s three
ongoing human clinical trials for dry age-related macular degeneration (dry
AMD) and Stargardt’s disease using human embryonic stem cell (hESC)-derived
retinal pigment epithelial (RPE) cells.

The full conference agenda is available here.

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc., is a biotechnology company applying cellular
technology in the field of regenerative medicine. For more information, visit
http://www.advancedcell.com.

Forward-Looking Statements

Statements in this news release regarding future financial and operating
results, future growth in research and development programs, potential
applications of our technology, opportunities for the company and any other
statements about the future expectations, beliefs, goals, plans, or prospects
expressed by management constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Any
statements that are not statements of historical fact (including statements
containing the words “will,” “believes,” “plans,” “anticipates,” “expects,”
“estimates,” and similar expressions) should also be considered to be
forward-looking statements. There are a number of important factors that could
cause actual results or events to differ materially from those indicated by
such forward-looking statements, including: limited operating history, need
for future capital, risks inherent in the development and commercialization of
potential products, protection of our intellectual property, and economic
conditions generally. Additional information on potential factors that could
affect our results and other risks and uncertainties are detailed from time to
time in the company’s periodic reports, including the report on Form 10-K for
the year ended December 31, 2011. Forward-looking statements are based on the
beliefs, opinions, and expectations of the company’s management at the time
they are made, and the company does not assume any obligation to update its
forward-looking statements if those beliefs, opinions, expectations, or other
circumstances should change. Forward-looking statements are based on the
beliefs, opinions, and expectations of the company’s management at the time
they are made, and the company does not assume any obligation to update its
forward-looking statements if those beliefs, opinions, expectations, or other
circumstances should change. There can be no assurance that the Company’s
clinical trials will be successful.

Contact:

Investors:
CEOcast, Inc.
James Young, 212-732-4300
or
Press:
ACT Corporate Communications
Bill Douglass, 646-450-3615
or
Russo Partners
Martina Schwarzkopf, Ph.D., 212-845-4292
 
Press spacebar to pause and continue. Press esc to stop.